Boxer Capital disclosed in a February 17, 2026 SEC filing that it purchased 135,000 shares of Celcuity, a clinical-stage biotech, in a move valued at roughly $11.10 million based on recent quarterly averages; the firm now reports Celcuity as a $22.44 million position representing about 4.9% of its 13F reportable assets. The filing shows the stake jumped by $18.00 million from the prior quarter due to combined trading activity and a sharp rise in Celcuity’s share price, which was $107.32 at the close on February 17, 2026. This article breaks down the trade, the holding’s place in Boxer Capital’s portfolio, company metrics, and key investor considerations. Read on for the facts you need without the promotional noise.
The SEC disclosure lists the purchase of 135,000 additional Celcuity shares during the fourth quarter of 2025, reflecting an aggressive accumulation late in the reporting period. Boxer Capital’s reported total holding in Celcuity is 225,000 shares after the purchase, and the filing ties that to a reported value of $22.44 million as of December 31, 2025. That jump in value versus the prior quarter is attributed both to the trading activity and to meaningful price appreciation over the quarter.
On a portfolio basis, Celcuity now sits among Boxer Capital’s larger positions but is not the biggest weight in the fund. The filing shows other top holdings include sizable positions in companies such as TNGX, RVMD, KOD, and KYMR, with TNGX listed as the largest holding at $96.36 million or roughly 21.1% of assets under management. Celcuity’s roughly 4.9% share of reportable assets signals meaningful conviction while still leaving room for diversification across the remainder of the fund.
Celcuity’s market snapshot in the filing and market data paints a company that has swung sharply in valuation terms over the last year. Market cap sits near $4.97 billion while trailing twelve month net income remains negative at ($162.72 million), a reminder of the typical biotech cash burn profile. The one-year price change listed was 741.1%, a dramatic run that outpaced broader indices by several hundred percentage points.
-
Top reported holdings and weights include TNGX at $96.36 million (21.1% of AUM), RVMD at $31.86 million (7.0%), KOD at $31.76 million (7.0%), KYMR at $25.61 million (5.6%), and CELC at $22.44 million (4.9%).
Celcuity is a clinical-stage company focused on precision oncology with its CELsignia diagnostic platform and investigational treatments such as Gedatolisib targeting breast cancer. The company combines diagnostic work with therapeutic development, aiming to pair patients to targeted drugs based on abnormal cellular signaling detected by its platform. That integrated approach is central to Celcuity’s strategy and is a key reason investors watch the stock closely.
Partnerships and licensing play an outsized role for clinical-stage biotechs, and Celcuity has arrangements that touch major industry players. Notably, the company holds a license agreement related to Gedatolisib with a large pharmaceutical firm, which underscores the potential commercialization pathways should clinical outcomes and regulatory reviews go favorably. Such agreements can accelerate development timelines or provide non-dilutive revenue avenues, but they do not remove development risk.
Investors reading the filing should remember that biotech stocks like Celcuity are inherently high risk and high reward. Clinical results, regulatory decisions, or trial setbacks can cause swift and large re-pricing, while positive readouts can propel dramatic gains. For many investors, spreading exposure through a diversified biotech ETF or holding a broader basket of health care names will be a less binary way to participate in sector upside while managing downside risk.
Boxer Capital’s purchase is a clear, bullish bet that Celcuity’s pipeline and diagnostic franchise have material upside, but the transaction does not mean the stock is suitable for every portfolio. The filing is a snapshot in time that reveals conviction from an institutional investor but does not remove the need for independent due diligence, timeline assessment, and risk tolerance analysis. Consider company fundamentals, cash runway, upcoming clinical milestones, and how an individual position fits into a personal allocation plan before acting.
Celcuity’s volatile performance over the last year shows how quickly market sentiment can swing in biotech, and Boxer Capital’s buying activity highlights one way professional managers respond to that volatility. The SEC filing provides a clear data point: 135,000 shares added in the quarter and a reported position value of $22.44 million, but that fact is only one input among many for anyone deciding whether the stock belongs in their own portfolio. Use it to inform further research rather than as a sole endorsement to buy or hold.
